Palifermin for the Reduction of Oral Mucositis In Single-dose Evaluation (PROMISE): A Randomized, Blinded, Active-control Trial of Palifermin (rHuKGF) to Evaluate Oral Mucositis in Subjects with Hematologic Malignancies Undergoing Fractionated Total Body Irradiation (fTBI) and High Dose Chemotherapy with Autologous Peripheral Blood Progenitor Cell (PBPC) Transplantation – Part A

Sponsor ID

20040212

Clinicaltrials.gov ID

EUCTIS ID

N/A

EudraCT ID

N/A

Study Details

Phase

Phase 3

Product

palifermin

Type

Interventional

Masking

N/A

Enrollment

N/A

Additional Study Details

Primary Outcome Measures

Not Available

Secondary Outcome Measures

Not Available

Study Synopsis

Available Language(s): English

No locations found.